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Abstract:
Background:
Coffee consumption has been shown to be associated with various health outcomes in observational
studies. However, evidence for its association with epithelial ovarian cancer (EOC) is inconsistent and
it is unclear whether these associations are causal.
Methods:
We used SNPs associated with (i) coffee and (ii) caffeine consumption to perform Mendelian
randomisation on EOC risk. We conducted a two-sample MR using genetic data on 44,062
individuals of European ancestry from the Ovarian Cancer Association Consortium (OCAC) and
combined instrumental variable estimates using a Wald-type ratio estimator.
Results:
For all EOC cases the causal odds ratio (COR) for genetically predicted consumption of one additional
cup of coffee per day was 0.92 (95% confidence interval: 0.79, 1.06). The COR was 0.90 (95% CI:
0.73, 1.10) for high-grade serous EOC. The COR for genetically predicted consumption of an
additional 80 mg caffeine was 1.01 (95% CI: 0.92, 1.11) for all EOC cases and 0.90 (95% CI: 0.73, 1.10)
for high-grade serous.
Conclusion:
We found no evidence indicative of a strong association between EOC risk and genetically predicted
coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier
observational studies and we were unable to rule out small protective associations.
Introduction:
Coffee is one of the most consumed beverages globally. A conventional cup of coffee can contain up
to 1,000 types of bioactive compounds including various kinds of antioxidants, aromatic compounds
and most importantly, caffeine. Caffeine has been found to suppress tumour growth in various
animal models(1, 2), making it a potentially relevant therapeutic agent in cancer studies. Other
compounds present in coffee are also found to have anti-inflammatory and anti-carcinogenic effects
such as the induction of enzymes responsible for carcinogen detoxification, inhibition of carcinogen
activation activities and stimulating intracellular antioxidant defence (1-3). Observational studies
have investigated coffee and caffeine intake in relation to type 2 diabetes (4, 5), depression (6),
insomnia (7) as well as various cancers (8, 9), but the directions of association have been
inconsistent across diseases (10).
There are growing concerns regarding coffee consumption in relation to women’s health. Epithelial
ovarian cancer (EOC) is a gynaecological malignancy with a high fatality rate. Approximately 151 900
women worldwide die of the disease annually (11). The high-grade serous histology is the most
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common EOC subtype (12). Whilst many individual studies have found conflicting directions of
association with coffee consumption and EOC risk, subsequent meta-analysis studies found no
evidence for an association (13-18). A more recent Danish study (19) suggested that moderate
increase in daily caffeine intake (by one cup of coffee per day) might be protective against invasive
EOC. Inconsistencies observed in the literature may be due to the lack of compatibility of categorical
definitions (size of cup, content, caffeine intensity, method of brewing) and differences in definitions
for baseline groups (i.e. non-drinkers). Some studies further combined consumption of tea and
coffee to investigate caffeine intake specifically. However, more importantly, all studies to date
examining the link between coffee/caffeine and EOC risk are observational studies where bias due to
confounding may make it difficult to draw reliable conclusions (20). For example, we can
hypothesize that women diagnosed with EOC may have temporal nutritional awareness and develop
aversion to caffeinated beverages (such as coffee and cola), which may distort the true underlying
association in case-control studies. Since randomized trials examining coffee consumption in relation
to ovarian risk have not been conducted, to work around these potential biases, we can apply an
instrumental variable technique, Mendelian randomization (MR) (21) to draw causal inferences on
coffee consumption.
Twin studies have shown that coffee consumption has a substantial genetic component, with an
estimated heritability ranging from 0.37–0.77 (22-24). This suggests that coffee consumption may
be a suitable trait for MR studies. In this study we aim to refine the relationship between coffee and
EOC susceptibility. We hypothesize that genetic predisposition towards higher coffee intake is
inversely associated with i) overall EOC susceptibility and ii) high-grade serous EOC susceptibility,
and draw inference on causality via MR.
Methods:
Data source
Participants for this study were drawn from the Ovarian Cancer Association Consortium (OCAC).
Genotyping was performed using the customised Infinium OncoArray-500K array (Illumina) (25)
consisting of ~322 000 variants. OncoArray data were available for 59 115 samples across 71 study
cohorts worldwide, of which 56 479 passed initial quality control protocols. Each individual was
assigned values to indicate the proportion of European, African or Asian ancestry they inherited
based on genetic makeup, using principal component analysis. These values sum up to 1 and are
used to categorise the subjects into one of the intercontinental ancestry groups. Following that,
imputation into the 1000 Genomes Project reference panel was carried out with pre-phasing using
SHAPEIT and IMPUTE2 (26, 27). First-degree related individuals and duplicated samples (n=1 732)
were removed. DNA samples from women of non-European ancestry were excluded for this study.
The total sample size used in this study was 44 062 women of European ancestry (Table 1 shows a
breakdown of the sample size by EOC histology). Baseline characteristics of our study samples from
OCAC according to weight, age, smoking status and other potential confounders are summarised in
Supplementary Table 1.
Genetic variants for the MR analyses were identified through an extensive review of published
GWAS findings for coffee, tea and/or caffeine consumption (28-33). SNPs associated with coffee
consumption (measured as cups/day) that were considered for use were rs1481012 in the ABCG2
gene, rs6968554 in the AHR gene, rs2470893 in the CYP1A2 gene, rs17685 in the POR gene and
rs6265 in the BDNF gene. In our subsequent analysis, we investigated whether the association with
coffee intake (in cups per day) onto ovarian cancer was driven mainly by genetic predisposition for
altered caffeine intake. SNPs reported to show association with caffeine and considered for use here
were rs6968865 from the AHR gene and rs2472297 from the CYP1A2 gene. All of the SNPs
investigated were either directly genotyped or imputed with high quality (info-score > 0.9). Although
these variants are different SNPs in AHR and CYP1A2, they are in high linkage-disequillibrium
(ݎଶ=0.8), see discussion for more detail. In order to ensure that our SNPs of interest are strong
instruments, we examined the statistical evidence in the literature for their association with coffee
and with caffeine consumption respectively. The variance on coffee consumption explained by a
particular SNP can be derived using ݎௌே௉ଶ = 2݌(1 − ݌)ߚଶ/ߪଶ where ݎௌே௉ଶ refers to the variance
explained by the SNP, ݌ refers to the MAF of the SNP, ߚ is the measured magnitude of association
per effect allele and ߪଶis the coffee trait variance. The variance explained by our SNP instruments
can hence be obtained by linearly summing up ݎௌே௉ଶ across each independent SNP instrument. We
subsequently tested each SNP against several potential confounders. For each of age at menarche,
measures of glycaemia, education attainment, BMI, waist-hip ratio, body fat and smoking behaviour,
we extracted previously published results from publicly available GWAS datasets (full details plus
references in supplementary table 3).
Causal Effect estimation
To perform MR we utilised a two sample statistical model to estimate the magnitude of association
between coffee consumption and ovarian cancer using summary statistics (34). We fitted an additive
model in SNPTEST (35) to test for association between each SNP and ovarian cancer status. Within-
ancestry principal components (PC1-PC9) were fitted to remove potential bias arising from intra-
ethnic population difference. Additional covariates that might be confounders such as BMI, smoking
status and alcohol consumption were not available for all the genotyped OCAC participants and
hence were not included as covariates (although subject to the assumptions of MR, not including
these potential confounders as covariates will not bias our results) to maximize sample size. The
genomic control lambda value was computed using 483 972 SNPs genome-wide to assess the
possibility of population stratification biasing the association between allele frequencies and
phenotype.
For both coffee and caffeine consumption we used the Wald-type ratio estimator (36) to combine
the SNP-estimates which uses the SNP-risk factor and SNP-cancer magnitude of association
estimates to calculate the aggregated causal effect. We estimated a causal OR (COR) for all ovarian
cancer and for the high grade serous subtype. High-grade serous was the only histological subtype
with sufficient numbers for sub-set analysis.
Results:
SNP Selection
We shortlisted a total of 4 independent SNPs (rs1481012, rs6968554, rs2470893, rs17685) as proxies
for genetically determined coffee consumption behaviour (31). For the analysis on caffeine, we used
2 SNPs (rs6968865,rs2472297) (33) as genetic proxies for total caffeine consumption per day (in
mg). Each of these SNPs is robustly associated with p-values less than p<5 × 10ି଼ for coffee
consumption in the original coffee GWAS. Due to the smaller sample size in the published analysis
for caffeine consumption, the published p-values for the effects of rs6968865 and rs2472297 on
caffeine consumption were not as strong as those for the SNP-coffee associations but both of the
SNPs combined associate with caffeine consumption with a p-value=3.74 × 10ିଵସ (33), with its
direction of association verified in an Australian sample (Supplementary A1). Each of the SNPs thus
satisfies the strong MR instrument criterion (F>>10).
In our pleiotropy assessment, the SNP rs6265 in the BDNF gene was found to have pleiotropic effects
on other traits of relevance to ovarian cancer (BMI and age of menarche, supplementary material)
so it was excluded from our analyses. After removing BDNF, the 4 coffee SNPs combined explain
about ~1.2% of the variation in coffee intake (31), whereas the 2 SNPs combined for our MR caffeine
study explain about ~1.3% of the variation in caffeine intake (33). We also tested the association
between established ovarian cancer risk factors (oral contraceptive use, estrogen use, parity) and
our SNPs of interest. The results of our pleiotropy assessment are available in Supplementary Table
3(publicly available GWAS) and Supplementary Table 4 (OCAC dataset). In brief, no associations were
found above chance level and we conclude that the assumptions of no-pleiotropy is not violated. In
particular, coffee consumption and cigarette consumption are correlated in some populations but
our chosen SNPs are not associated with smoking (Supplementary Table 3).
Instrumental variable analysis
The SNP-cancer association results for each genetic instrument used are available in Supplementary
Table 2. We estimated the causal odds ratio associated with a genetically predicted one cup per day
change in coffee consumption. For all EOC cases the COR for consuming one additional cup of coffee
per day was 0.92 (95% confidence interval, CI: 0.79, 1.06). For high-grade serous EOC, the COR was
0.90 (95% CI: 0.73, 1.10). We also performed an additional analysis to investigate caffeine
consumption, with the COR scaled in terms of an 80mg increase (the approximate caffeine content
in a conventional cup of coffee). The COR for consuming an additional 80mg of caffeine was 1.01 (CI:
0.92, 1.11) for all EOC cases and 0.90 (CI: 0.73, 1.10) for high-grade serous. The CORs derived from
individual SNP instruments are shown in Figure 1 for coffee consumption; and Figure 2 for caffeine
intake.
Population Stratification and confounding
Due to the missing covariate data on some OCAC participants (see Supplementary Table 1), the
analyses were performed by only fitting the first 9 genetic (ancestral) principal components as
covariates. In a sensitivity analysis using participants with confounder data available (n~11 400),
adjustment for potential confounders (age of menarche, education level, number of pregnancies,
oral contraceptive use, estrogen use, smoking and BMI) did not change the magnitude of the SNP-
disease associations (See Supplementary Table 6). The genomic control lambda was 1.076 (ߣଵ଴଴଴ =1.007, LD-score intercept=1.032) demonstrating that there is little evidence for inflation of the
genome-wide association statistics due to population stratification. Plots of the ancestral principal
components (PC1 against PC2) between cases and controls indicate that the cases and controls are
homogeneous (See Supplementary Figure 1 and 2).
Discussion:
In our study sample of 44 062 European participants from OCAC, we found no evidence suggestive of
a large causal association between (genetically predicted) coffee consumption and overall EOC risk
nor on high-grade serous EOC. Similarly, our findings consistently suggest no causal link between
caffeine intake and EOC susceptibility.
Research in context
Most epidemiological studies in the past investigated the association of EOC with coffee
consumption by assessing the difference in EOC risk among non-coffee drinkers and strong coffee
drinkers. Consumption of > 3 cups of coffee per day was used as a benchmark to indicate strong
coffee drinking behaviour. To compare our results, we rescaled findings from these observational
studies to reflect an averaged moderate change in daily coffee consumption (1 cup of coffee per
day) using Equation 1 in Supplementary material. The resultant estimates from our study were
broadly compatible with results of previous meta-analyses (Figure 3).
Although some individual observational studies have found associations between coffee
consumption and risk of EOC, meta-analyses have found no evidence to show that coffee
consumption protects against EOC (13). However, a common criticism of observational studies is
inconsistency in the definition of categorised consumption (i.e. different studies adopt different
definitions of heavy drinkers) and the variability in types of coffee beverages, which may differ
strongly in terms of nutritional content (most importantly, caffeine). These systematic differences
can make the interpretation of meta-analysed findings difficult. Moreover, it is difficult to rule out
the potential effects of selection bias in case-control studies and of unmeasured or uncontrolled
confounding in observational studies in general. In contrast, here we use genetically predicted coffee
intake to provide more uniform estimates of coffee consumption in a large sample size (coffee
GWAS (31), n>80 000). Our 2-sample MR design allows us to investigate the underlying association
without the issue of potential confounders such as education level, alcohol use and smoking
behaviour, which was established by earlier studies to be strongly correlated to coffee consumption.
In our pleiotropy assessment, the SNP instruments we employ are not associated with these
potential confounders (Supplementary table 3).
Even though the MR analyses were performed separately for coffee consumption and caffeine
intake with independent SNPs within each study, the inference we draw from these findings are not
independent. This is due to the fact that, for each study the most important single SNPs (rs2470893
in CYP1A2 which explains ~0.5% of the variance in coffee consumption (31) and rs2472297 in
CYP1A2 which explains ~0.8% of the variance in caffeine consumption (33)) are in high linkage
disequilibrium (r2=0.7 between the two SNPs). Hence, the effect of those SNPs (rs2470893,
rs2472297) on coffee and caffeine consumption may not be separable (i.e. CYP1A2 is involved in
metabolizing common bioactive compounds in coffee). The same applies for SNP rs6968865 and
rs6968554 in AHR.
Previous studies have highlighted a potential role of caffeine in inducing p53-dependent (tumour
suppression gene) apoptosis (37). Since TP53 mutations are found in almost all high-grade serous
EOC (38), an analysis of high-grade serous alone was of particular interest. However in our study,
coffee and caffeine intake did not appear to be associated with any risk of high-grade serous
carcinoma among Europeans.
Strengths and limitations
One of the strength of our study is that participants used in our analyses were all of European
ancestry, limiting potential bias due to population heterogeneity. Furthermore, the use of ancestral
principal components to define ethnicity also prevents heritage-reporting errors (i.e. ethnicity was
determined based on SNP profiles, as summarised by ancestry principal components to avoid self-
reporting biases). In our MR study, the use of GWAS findings to predict coffee/caffeine consumption
rather than relying on self-reports of consumption should remove misclassification biases that can
plague self-reported studies and contribute to statistical heterogeneity in meta-analyses of
observational studies. Since coffee consumption generally stabilizes during adulthood, our 2-sample
MR approach is protected by potential biases due to apparent age differences between the SNP-
coffee samples and the OCAC samples. In other words, the estimated SNP-coffee association during
adulthood remain a robust genetic predisposition to lifetime coffee intake behaviour.
For our MR to infer about causality, several MR assumptions have to be met. Firstly, the instruments
(SNPs) used here were robustly associated (with F>>10) to coffee and caffeine intake respectively.
Secondly, he SNPs used in this study showed no evidence for any pleiotropic effects that may
confound the association with EOC susceptibility. The third MR assumption, that the genetic variants
used in our study only influence EOC susceptibility through mediating coffee consumption, can be
difficult to test directly. However, previous studies have examined the role of CYP1A1, CYP1A2 and
AHR in detail (28, 29, 32, 39). In each case, a SNP in or near the gene has been implicated by GWAS
and we assume that the action of the SNP on coffee consumption is via the specified gene. Taking
each in turn, CYP1A2 encodes the primary enzyme that metabolises caffeine in the liver, while
CYP1A1 encodes protein that metabolises polycyclic aromatic hydrocarbons, which are more
commonly found in coffee beans. The AHR gene is known to induce both CYP1A1 and CYP1A2 via a
DNA binding mechanism (29) and is also responsible in detection of toxic chemicals (39). Despite
coffee intake being strongly correlated with smoking, our pleiotropy assessment indicated that none
of the SNPs appear to be associated (Bonferroni corrected p-value > 0.05) with smoking behaviours.
Moreover, the lack of a main effect of the SNPs on smoking makes a coffee-smoking interaction less
likely - Thus, it seems very improbable that these SNPs directly influence ovarian cancer through
other independent biological processes.
Although we found no evidence supportive of an association between the SNPs used and common
risk factors for EOC (40, 41)(e.g. smoking, oral contraceptive use, parity, etc.), it is hard to rule out
directly possibilities of residual pleiotropy. However, suppose that a SNP has a strong pleiotropic
effect which biases our results - for us to observe the null causal odds ratio we find here, the other
SNPs (or some combination of SNPs) must act pleiotropically in the opposite direction and with
similar magnitude to the first SNP. Since this is unlikely, it is unlikely that pleiotropic effects have a
considerable influence on our non-causality conclusion.
There are some limitations that should also be considered in our analyses. Firstly, our study was
performed using only European ancestry women and our findings may not generalize to other
populations. Even though our SNPs greatly exceed the traditional strong instruments criteria (F>10),
our SNPs combined only account for a relatively small proportion of variation (~1.2%) in coffee
consumption (cups per day), potentially leading to problems in power when applying MR. With a
relatively small proportion of variance explained, we must extrapolate from small changes in
predicted coffee consumption. If the sample size in our data linking genotype to ovarian cancer risk
were small, the overall estimates of the causal odds ratio would be too large to be useful. However,
as we have available a large dataset from an international consortium, the overall standard error in
our causal odds ratio is relatively small, allowing us to make clear statements on the likely limits of
the causal effect of coffee consumption on ovarian cancer (e.g. for all histologies the causal OR is
0.92 with 95% confidence interval 0.79, 1.06).
The precision of our estimates is good for the most common subtype high grade serous (Causal OR
0.90 with 95% CI: 0.73, 1.10) but for the less common subtypes taken individually our power is low;
we similarly have insufficient power to perform stratified analyses (e.g. based on groups with
particular smoking or BMI status).
The difference in coffee consumption as quantified in our MR analysis can be hard to interpret. In
our analysis, CORs are calculated based on one additional cup of coffee per day averaging across all
possible quantities of coffee consumption among regular coffee drinkers (including non-drinkers).
This made it difficult to compare our estimates reliably with those from studies that investigated
extreme ends of the trait distribution (heavy coffee drinking (>5 cups) and/or coffee drinkers to non-
drinkers). Here, it is difficult for our study to completely rule out previous findings that showed
positive associations of EOC when comparing very heavy coffee-drinkers to other categories (13).
That is, our findings only infer that moderate differences in coffee consumption (averaging over the
entire trait distribution) do not influence risk of EOC as the MR framework assumes that modifiable
exposures linearly affect the underlying risk factor; which might be violated if the outcome to
exposure relationship is non-linear (follows a J-shaped curve).
An additional consideration is how to handle non-coffee drinkers. For caffeine this is not an issue
because non-users are included in the SNP association studies. For coffee consumption, in our main
analysis, we focus on “cups per day” coffee consumption. However, the GWASs to date on “cups per
day” in coffee consumers also found (31) that the same SNPs were also strongly associated with
drinking status (“high” versus “low/no” coffee consumption). Hence our findings in support of non-
causality of “cups per day” probably extend to alternative definitions such as “high” versus “low/no”
status.
We found no evidence indicative of a strong association between EOC risk and genetically predicted
coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier
observational studies and we were unable to rule out small protective associations. Our MR based
results are more readily interpretable than previous observational studies because they are unlikely
to be adversely affected by confounding biases which can invalidate the conclusions from
observational studies.
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Let N be the number of ordered consumption categories, and ܱ௜be the Odds ratio of the -݅th category to the lowest category.
We have that ܱଵ = 1 (trivial). Then the averaged change in risk (Odds ratio) per additional cup of coffee per day, ஺ܱ௩௘ is given by
஺ܱ௩௘ = ݁ݔ݌( 1ܰ − 1෍ log(ܱ௜)݅− 1ே
௜ୀଶ
)
A1 Exploring the role of SNP instruments in caffeine consumption
It is important to note that the sample size of the genetic association study for caffeine intake (1) were much smaller than those in the published
coffee GWAS. Although we opted to characterize the effect of our chosen instrumental variable SNPs on genetically predicted caffeine
consumption using published data, we also confirmed the role these SNPs play using data on directly measured (self-reported) caffeine intake
(through tea, cola, chocolate and coffee) from one of the studies participating in OCAC - 2,347 participants from the Australian Ovarian Cancer
Study (see Supplementary Table 5). The results for the caffeine SNPs (rs6968865 and rs2472297) were consistent with the published findings (1).
This serves as a validation of instrument strength, providing reassurance that the pattern of association of these SNPs is consistent across studies
and that the results from our two-sample MR approach are robust (i.e. for the scenario where the SNP-caffeine associations come from a
different sample than SNP-disease associations).
Table 1: Baseline Characteristics of OCAC Participants




Weight(1yr ago) 68.2(60.3,80.0) 69.0(60.3,81.6)




Less than high school 1,659 1,516
High school or more 9,278 9,678
Missing 12,442 9,489
Pregnancy
Ever pregnant 12,276 11,117









Current smoker 1,242 1,669
Former smoker 3,324 3,509








Never used OC 3,720 5,198
Missing 9,869 7,286
Estrogen
Ever used estrogen 1,438 1,323
Never used 7,296 7,160
Missing 14,645 12,200
Table 2: Association of SNPs to risk of all EOC and High-grade serous EOC (HS).







Cornelis et al. ABCG2 rs1481012 A G 0.06 0.01 cups/ day 0.019 0.022 0.041 0.031
Cornelis et al. AHR rs6968554 G A 0.13 0.01 cups/day -0.020 0.014 -0.032 0.02
Cornelis et al. CYP1A1 rs2470893 T C 0.12 0.01 cups/ day 0.011 0.015 0.017 0.021
Cornelis et al. POR rs17685 A G 0.07 0.01 cups/ day -0.033 0.015 -0.043 0.021
McMahon et al. AHR rs6968865 T A 14.6 3.1 caffeine per day (mg) -0.018 0.014 -0.032 0.02
McMahon et al. CYP1A2 rs2472297 T C 21.4 3.4 caffeine per day (mg) 0.012 0.017 0.025 0.023









Menarche (2) ReproGen –
Age at
menarche
21102462 87,802 rs2470893 T C -0.004 5.30E-01
rs2472297 T C -0.007 3.30E-01
rs6968554 A G 0.001 8.40E-01
rs6968865 A T 0.003 6.40E-01
rs17685 A G 0.012 1.10E-01






20081858 46,186 rs2470893 T C -0.006 0.09935
rs2472297 T C -0.009 0.03103
rs6968554 A G 0.004 0.2863
rs6968865 A T 0.004 0.2591
rs17685 A G -0.005 0.2505
rs6265 T C 0.004 0.302
MAGIC -
Fasting insulin
20081858 46,186 rs2470893 T C -0.003 0.3833
rs2472297 T C -0.004 0.257
rs6968554 A G 0.000 0.9575
rs6968865 A T 0.000 0.8843
rs17685 A G 0.002 0.622






23722424 126,559 rs2470893 T C -0.002 0.714
rs2472297 T C -0.001 0.8807
rs6968554 A G 0.000 0.9079
rs6968865 A T -0.002 0.7121
rs17685 A G 0.006 0.1748




23722424 126,559 rs2470893 T C -0.002 0.2872
rs2472297 T C -0.001 0.599
rs6968554 A G -0.001 0.5006
rs6968865 A T -0.002 0.3829
rs17685 A G 0.005 0.03126






20881960 183,727 rs2470893 T C 0.001 0.83
rs2472297 T C -0.002 0.7
rs6968554 A G 0.009 0.0039
rs6968865 A T 0.008 0.018
rs17685 A G -0.006 0.13
rs6265 T C 0.007 0.063
GIANT - Waist
hip ratio
20935629 77,167 rs2470893 T C 0.009 0.022
rs2472297 T C 0.007 0.08
rs6968554 G A 0.006 0.059
rs17685 A G 0.006 0.28
rs6265 C T 0.020 2.30E-06
Obesity (7) GIANT – Body
Mass Index
25673413 339,224 rs2470893 T C 0.008 0.01849
rs2472297 T C 0.005 0.1683
rs6968554 G A 0.009 0.004364
rs6968865 T A 0.006 0.172
rs17685 A G 0.010 0.03026
rs6265 C T 0.042 2.99E-27
GIANT –
BMI>30
25673413 339,224 rs17685 G A 0.003 9.50E-01
rs2470893 T C 0.006 8.80E-01
rs2472297 C T 0.029 5.40E-01
rs6968554 G A 0.026 4.80E-01
rs6968865 T A 0.031 4.10E-01






20418890 68,028 rs2470893 T C -0.213 0.0274
rs2472297 T C -0.161 0.2285
rs6968554 A G 0.056 0.5346
rs6968865 A T 0.050 0.5848
rs17685 A G 0.139 0.3136




20418890 74,035 rs2470893 T C 0.009 0.5164
rs2472297 T C -0.007 0.7498
rs6968554 A G 0.012 0.3518
rs6968865 A T 0.013 0.3114
rs17685 A G -0.007 0.75
rs6265 T C -0.063 1.72E-05
Body Fat (9) Global Lipid
Consortium -
HDL
24097068 187,167 rs2470893 T C 0.005 0.3613
rs2472297 T C 0.004 0.3967
rs6968554 A G 0.018 2.81E-06
rs6968865 A T 0.015 0.009228




24097068 173,082 rs2470893 T C 0.008 0.09758
rs2472297 T C 0.005 0.3315
rs6968554 G A 0.006 0.1251
rs6968865 T A 0.006 0.3134





24097068 187,365 rs2470893 T C 0.006 0.2177
rs2472297 T C 0.003 0.4886
rs6968554 G A 0.003 0.4247
rs6968865 T A 0.004 0.3928
rs6265 C T 0.005 0.2669
Global Lipid
Consortium -
24097068 177,861 rs2470893 C T 0.009 0.1374
Triglyceride
rs2472297 C T 0.006 0.352
rs6968554 G A 0.020 1.17E-06
rs6968865 T A 0.011 0.139
rs6265 C T 0.015 0.001204
Table 4: Pleiotropy assessment – Association of coffee/caffeine genetic variants with confounding variables using OCAC participant data
Risk Factor Unit of Measurement Sample
size
SNP ID Risk Allele Other Allele Magnitude of
Association
P-Value
Estrogen use No. of months 16,337 rs1481012 G A -0.0144 0.4292
rs6968554 G A 0.0100 0.3826
rs2470893 T C -0.0299 0.0130
rs17685 A G 0.0144 0.2437
rs6968865 T A 0.0113 0.3224
rs2472297 T C -0.0258 0.0601
Oral Contraceptive use No. of months 25,699 rs1481012 G A 0.0162 0.2585
rs6968554 G A -0.0044 0.6278
rs2470893 T C -0.0072 0.4465
rs17685 A G -0.0044 0.6498
rs6968865 T A -0.0050 0.5847
rs2472297 T C -0.0081 0.4528
Parity No. of pregnancies
(regardless of outcome)
25,720 rs1481012 G A 0.0057 0.6945
rs6968554 G A -0.0087 0.3382
rs2470893 T C 0.0040 0.6714
rs17685 A G 0.0094 0.3372
rs6968865 T C -0.0054 0.6209
rs2472297 T A -0.0099 0.2792
Table 5: Sensitivity analysis - SNP association on caffeine consumption among OCAC AOCS participants (N=2,347)
SNP Chromosome Trait Risk Allele Other Allele Magnitude of association (mg) S.E. P-value
rs6968865 7 Caffeine T A 11.7800648 5.83759195 0.043718
rs2472297 15 Caffeine T C 9.823905502 6.71210422 0.143446
AOCS refers to the Australian Ovarian Cancer Study.
Table 6: Sensitivity analysis – Adjustment of confounding variables in SNP-association
6A. Set 1: OCAC Participants with information on confounders available (excluding BMI), n=11,366
Model adjusted for potential confounders
(exclude BMI)
Original model
Gene SNP EA NEA Pvalue Beta S.E. Pvalue Beta S.E.
Coffee
ABCG2 rs1481012 G A 0.7354 -0.0152 0.0449 0.5689 -0.0251 0.0440
AHR rs6968554 G A 0.7291 0.0098 0.0284 0.7607 0.0085 0.0279
CYP1A1 rs2470893 T C 0.2732 0.0326 0.0298 0.3004 0.0303 0.0292
POR rs17685 A G 0.0074 -0.0819 0.0306 0.0085 -0.0791 0.0301
Caffeine
AHR rs6968865 T A 0.7546 0.0089 0.0283 0.7671 0.0082 0.0278
CYP1A2 rs2472297 T C 0.5422 0.0205 0.0337 0.6052 0.0171 0.0331
6B. Set 2: OCAC Participants with information on confounders available including BMI, n=4,718
Model adjusted for covariates including BMI Original model
Gene SNP EA NEA Pvalue Beta S.E. Pvalue Beta S.E.
Coffee
ABCG2 rs1481012 G A 0.3318 0.0674 0.0694 0.3379 0.0650 0.0679
AHR rs6968554 G A 0.6501 -0.0200 0.0440 0.8276 -0.0094 0.0430
CYP1A1 rs2470893 T C 0.4851 0.0326 0.0467 0.5542 0.0270 0.0457
POR rs17685 A G 0.0120 -0.1191 0.0475 0.0107 -0.1182 0.0464
Caffeine
AHR rs6968865 T A 0.7155 -0.0160 0.0440 0.8935 -0.0057 0.0429
CYP1A2 rs2472297 T C 0.3480 0.0500 0.0533 0.3399 0.0497 0.0521
EA refers to the effect allele, i.e. allele associated with increased coffee consumption; NEA refers to the non-effect allele.
The adjusted model is a logistic regression model on ovarian cancer status adjusted for 9 genetic principal components and covariates:
education attainment, age at menarche, number of pregnancies, smoking, oral contraceptive use, estrogen use (and BMI in Set 2). The original
model is a logistic model adjusted for only the 9 genetic principal components. The analysis on BMI is separated (reported in 7B) due to high
number of missing values on BMI from the participants.








































































CHN China 0 0 0 0 0 0 0 0 0 0
CNI CNIO Ovarian
Cancer Study



















GOCS Germany 376 202 180 117 90 14 18 19 6 19




































HUOCS Germany 124 49 47 17 11 2 0 2 1 0
ICN (merged to
UK studies)







































MALOVA Denmark 644 384 384 249 190 45 52 37 29 0
MAS Malaysia
Ovarian















(none) USA 297 307 292 188 157 19 15 7 14 13
MEC Multiethnic
Cohort Study

































































PLCO USA 1117 263 233 130 0 0 19 5 8 22
POC Polish Ovarian
Cancer Study





POCS Poland 0 272 245 114 73 5 35 15 9 19
PVD Danish Pelvic
Mass Study
















(none) USA 0 99 95 70 0 0 7 6 3 1









SEARCH UK 1823 2148 1945 890 431 459 255 247 181 198
SIS The Sister
Study































SWHS China 0 0 0 0 0 0 0 0 0 0
SZB (merged to
POC)
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*LMP refers to Low-malignant Potential.
Figure 1a: PCA plot of OCAC participants with EOC
Figure 1b: PCA plot of OCAC participants with high grade serous
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All EOC cases¥ 20,683
¥Including unclassified and unknown serous/mucinous ovarian tumours.
Note: A complete breakdown of the EOC cases by each participating study is provided in
Supplementary Material.
